Innovations and revolutions in reducing retinal ganglion cell loss in glaucoma

M Kelada, D Hill, TE Yap, H Manzar… - Expert Review of …, 2021 - Taylor & Francis
Introduction Glaucoma remains the leading cause of irreversible blindness. Although the
loss of retinal ganglion cells (RGCs) is an established hallmark of glaucoma, reduction of …

[HTML][HTML] Suppl 1: M5: Present and new treatment strategies in the management of glaucoma

M Kolko - The open ophthalmology journal, 2015 - ncbi.nlm.nih.gov
Glaucoma is a neurodegenerative disease characterized by retinal ganglion cell (RGC)
death and axonal loss. It remains a major cause of blindness worldwide. All current …

Changing therapeutic paradigms in glaucoma management

R David - Expert opinion on investigational drugs, 1998 - Taylor & Francis
Glaucoma is a family of diseases commonly characterised by progressive optic neuropathy
with associated visual field deficits for which elevated intraocular pressure (IOP) is one of the …

Recent Research Efforts to Achieve Neuroprotection, Progression and Treatment of Glaucoma

A Jacobi, T van Zyl - Klinische Monatsblatter fur Augenheilkunde, 2020 - europepmc.org
Glaucoma is a neurodegenerative disease that leads to irreversible blindness over time. Its
defining feature is the loss of retinal ganglion cells (RGCs) in the eye and their axons in the …

Neuroprotective strategies in glaucoma

CA Gossman, J Christie, MK Webster… - Current …, 2016 - ingentaconnect.com
Background: Glaucoma is characterized as a neuropathic disease that causes progressive
degeneration of retinal ganglion cells (RGCs) in the retina, resulting in irreversible loss of …

An Update on Pharmacotherapy of Glaucoma

S Virani, P Rewri - 2023 - preprints.org
Progressive loss of retinal ganglionic cells (RGC) causes blindness in glaucoma. Elevated
intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the …

[PDF][PDF] Current trends in glaucoma: what about neuroprotection?

S Pinal, E Vecino - Eye Research Developments, 2009 - researchgate.net
Glaucoma is an optic neuropathy, considered as the second leading cause of blindness
worldwide. Glaucoma is characterized by selective death of retinal ganglion cells (RGC) and …

[HTML][HTML] A Narrative Review of Pharmacotherapy of Glaucoma

S Virani, P Rewri - Future Pharmacology, 2024 - mdpi.com
Progressive loss of retinal ganglionic cells (RGC) causes degeneration of optic nerve axons,
which leads to blindness in glaucoma. Elevated intraocular pressure (IOP) is the most …

Advances in Glaucoma Treatment

G Labiris - 2024 - mdpi.com
Advances in Glaucoma Treatment | MDPI Books MDPI Books Publish with Us Submit
Support Register Login Book cover Look inside Format Hardback License © by the authors …

Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma

KS Yadav, S Sharma, VY Londhe - Life sciences, 2020 - Elsevier
Glaucoma, a neurodegenerative disorder is characterized by damage of ganglion cells of
retina and also its axons. The manner of progression of disease and retinal ganglion cells …